NAFLD and thyroid function: pathophysiological and therapeutic considerations

被引：59

作者：

Hatziagelaki, Erifili ^{[1
]}

Paschou, Stavroula A. ^{[2
,3
]}

Schoen, Martin ^{[4
,5
]}

Psaltopoulou, Theodora ^{[2
,3
]}

Roden, Michael ^{[4
,5
,6
,7
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Diabet Ctr, Dept Internal Med 2, Athens, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Hosp, Endocrine Unit,Dept Clin Therapeut, Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Diabet Ctr, Sch Med,Dept Clin Therapeut, Athens, Greece

[4] Heinrich Heine Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Ctr Diabet Res, Dusseldorf, Germany

[5] German Ctr Diabet Res DZD, Partner Dusseldorf, Munich, Germany

[6] Heinrich Heine Univ Dusseldorf, Dept Endocrinol & Diabetol, Med Fac, Dusseldorf, Germany

[7] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2022年 / 33卷 / 11期

关键词：

FATTY LIVER-DISEASE; RECEPTOR-BETA AGONISTS; HORMONE RECEPTOR; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; INSULIN-RESISTANCE; GLOBAL EPIDEMIOLOGY; ENERGY-EXPENDITURE; HEPATIC STEATOSIS; GENE-EXPRESSION;

D O I：

10.1016/j.tem.2022.08.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nonalcoholic fatty liver disease (NAFLD) is a worldwide rising challenge because of hepatic, but also extrahepatic, complications. Thyroid hormones are master regulators of energy and lipid homeostasis, and the presence of abnormal thyroid function in NAFLD suggests pathogenic relationships. Specifically, persons with hypothyroidism feature dyslipidemia and lower hepatic beta-oxidation, which favors accumulation of triglycerides and lipotoxins, insulin resistance, and subsequently de novo lipogenesis. Recent studies indicate that liver-specific thyroid hormone receptor beta agonists are effective for the treatment of NAFLD, likely due to improved lipid homeostasis and mitochondrial respiration, which, in turn, may contribute to a reduced risk of NAFLD progression. Taken together, the possible coexistence of thyroid disease and NAFLD calls for increased awareness and optimized strategies for mutual screening and management.

引用

页码：755 / 768

页数：14

共 113 条

[11] Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight [J].

Baxter, JD ;

Webb, P ;

Grover, G ;

Scanlan, TS .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (04) :154-157

[12] An assessment by the Statin Liver Safety Task Force: 2014 update [J].

Bays, Harold ;

Cohen, David E. ;

Chalasani, Naga ;

Harrison, Stephen A. .

JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) :S47-S57

[13] The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans [J].

Berkenstam, Anders ;

Kristensen, Jens ;

Mellstrom, Karin ;

Carlsson, Bo ;

Malm, Johan ;

Rehnmark, Stefan ;

Garg, Neeraj ;

Andersson, Carl Magnus ;

Rudling, Mats ;

Sjoberg, Folke ;

Angelin, Bo ;

Baxter, John D. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (02) :663-667

[14] Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism [J].

Bohinc, Brittany N. ;

Michelotti, Gregory ;

Xie, Guanhua ;

Pang, Herbert ;

Suzuki, Ayako ;

Guy, Cynthia D. ;

Piercy, Dawn ;

Kruger, Leandi ;

Swiderska-Syn, Marzena ;

Machado, Mariana ;

Pereira, Thiago ;

Zavacki, Ann Marie ;

Abdelmalek, Manal ;

Diehl, Anna Mae .

ENDOCRINOLOGY, 2014, 155 (11) :4591-4601

[15] Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression [J].

Bruinstroop, Eveline ;

Zhou, Jin ;

Tripathi, Madhulika ;

Yau, Winifred W. ;

Boelen, Anita ;

Singh, Brijesh Kumar ;

Yen, Paul M. .

MOLECULAR METABOLISM, 2021, 53

[16] Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD [J].

Bruinstroop, Eveline ;

Dalan, Rinkoo ;

Cao, Yang ;

Bee, Yong Mong ;

Chandran, Kurumbian ;

Cho, Li Wei ;

Soh, Shui Boon ;

Teo, Eng Kiong ;

Toh, Sue-Anne ;

Leow, Melvin Khee Shing ;

Sinha, Rohit A. ;

Sadananthan, Suresh Anand ;

Michael, Navin ;

Stapleton, Heather M. ;

Leung, Christopher ;

Angus, Peter W. ;

Patel, Sheila K. ;

Burrell, Louise M. ;

Lim, Su Chi ;

Sum, Chee Fang ;

Velan, S. Sendhil ;

Yen, Paul M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (07) :2698-2706

[17] Reduction of Hepatic Steatosis in Rats and Mice After Treatment with a Liver-Targeted Thyroid Hormone Receptor Agonist [J].

Cable, Edward E. ;

Finn, Patricia D. ;

Stebbins, Jeffrey W. ;

Hou, Jinzhao ;

Ito, Bruce R. ;

van Poelje, Paul D. ;

Linemeyer, David L. ;

Erion, Mark D. .

HEPATOLOGY, 2009, 49 (02) :407-417

[18] TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD [J].

Caddeo, Andrea ;

Kowalik, Marta Anna ;

Serra, Marina ;

Runfola, Massimiliano ;

Bacci, Andrea ;

Rapposelli, Simona ;

Columbano, Amedeo ;

Perra, Andrea .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)

[19] Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta [J].

Chaves, Carolina ;

Bruinstroop, Eveline ;

Refetoff, Samuel ;

Yen, Paul ;

Anselmo, Joao .

THYROID, 2021, 31 (07) :1127-1134

[20] The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD [J].

Chavez, Chandani Patel ;

Cusi, Kenneth ;

Kadiyala, Sushma .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (01) :29-38

← 1 2 3 4 5 6 7 8 9 10 →